SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 43.48 |
| Enterprise Value ($M) | 60.62 |
| Book Value ($M) | -75.22 |
| Book Value / Share | -2.17 |
| Price / Book | -0.58 |
| NCAV ($M) | -75.22 |
| NCAV / Share | -2.17 |
| Price / NCAV | -0.58 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | n/a |
| Return on Assets (ROA) | -3.95 |
| Return on Equity (ROE) | -63.86 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 0.03 |
| Current Ratio | 0.03 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 1.03 |
| Assets | 1.03 |
| Liabilities | 76.25 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G | Ayrton Capital LLC | 9.90 | ||
| 13G/A | Boothbay Fund Management, Llc | 0.00 | ||
| 13G/A | Atw Spac Management Llc | 0.00 | ||
| 13G/A | Polar Asset Management Partners Inc. | 7.70 | ||
| 13G/A | Weiss Asset Management LP | 0.00 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 83,960 | 42,570 | 197.23 | |
| 48,852 | 35,741 | 136.68 | |
| 29,645 | 49,450 | 59.95 | |
| 38,903 | 23,318 | 166.84 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| NRXP – NRx Pharmaceuticals, Inc. | NTBL – Notable Labs, Ltd. |
| NVCT – Nuvectis Pharma, Inc. | OCGN – Ocugen, Inc. |
| OCUP – Ocuphire Pharma, Inc. |
Financial data and stock pages provided by
Fintel.io